secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001140361-25-038030
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma: FDA accepts BLA resubmission for KRESLADI gene therapy; PDUFA March 28, 2026
--------------------------------------------------------------------------------

- FDA accepted BLA resubmission for KRESLADI (marne-cel) for severe LAD-I; PDUFA target date March 28, 2026.
- Phase 1/2 study showed 100% overall survival at 12 months; all endpoints met; well tolerated with no treatment-related SAEs.
- Company eligible for Rare Pediatric Disease Priority Review Voucher if KRESLADI is approved.
- Severe LAD-I is near-uniformly fatal in childhood; only current treatment is bone marrow transplant with substantial morbidity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125038030/0001140361-25-038030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125038030/ef20057000_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-038030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer